In mid-September, the U.S. Department of Justice (DOJ) announced that Abbott Laboratories will pay nearly $385 million to resolve allegations that it caused false claims to be submitted to federal and state programs.
The specific allegations, which initially were brought by three whistleblowers, are that Abbott failed to manufacture powdered infant formula at its Sturgis, Michigan, and Casa Grande, Arizona facilities in compliance with federal, state, and contractual requirements.
Why is that a False Claims Act case? Because more than half of all infant formula purchased in the United States is paid for with U.S. Department of Agriculture funds through the Special Supplemental Nutrition Program for Women, Infants and Children (WIC) program, which provides nutritional support to eligible participants. State Medicaid programs also cover and pay for certain infant formula. When a manufacturer delivers to the government a product that does not meet regulatory and contractual standards, that becomes a false claim on the taxpayer.
Of the settlement, about $348.7 million goes to the federal government, and about $36.3 million goes to state Medicaid programs. In settling the case, Abbott did not admit liability and maintains there is no evidence its formula caused illnesses behind a 2022 recall of its product.
Nevertheless, the allegations are striking. According to the whistleblowers’ qui tam complaint and the DOJ complaint, roof leaks were common at the Sturgis plant, and instead of a permanent fix, Abbott used umbrellas to divert the water – even though, the whistleblowers and DOJ say, corporate leadership understood that a wet environment raised contamination risk. DOJ and the whistleblowers allege Abbott kept running spray dryers after documenting cracks and pits in them, and lengthened the number of batches between cleanings to boost production.
Most troubling, DOJ and the whistleblowers allege Abbott intentionally did not test for bacterial growth, in order to avoid positive results. And where testing did show contamination, it allegedly did not disclose those results when the Food and Drug Administration (FDA) asked during its 2019 and 2022 inspections.
For context, the FDA 2022 inspection followed complaints that four infants had been hospitalized with rare bacterial infections, and two died. The Sturgis plant shut down, there was a recall that included Similac, and a nationwide formula shortage ensued. Acting Deputy Attorney General Trent McCotter said the Abbott settlement “makes clear the safety of our children is not negotiable.”
Here’s a point worth emphasizing. The FDA inspected the Sturgis plant in 2019 and again in 2022. However, inspection authority and site access did not surface the alleged misconduct. Whistleblowers did: three former Abbott employees – Scott Millard, Kristine Cooper, and Loren Cooper – worked in Abbott’s quality and maintenance operations. That matters. These are the people on the inside who see the dryers, the maintenance records, and the sampling decisions. They filed a qui tam lawsuit in the Western District of Michigan in October 2022, and the government later intervened.
For bringing that information forward, they will share $69 million as their whistleblower share, roughly 20 percent of the government’s recovery.
Think about how this fraud looks from the government’s side. On paper, it is an ordinary invoice for infant formula. Nothing on a claim form reveals a leaking roof, a cracked dryer, or a test that was never run. Only insiders know.
That is how whistleblowers protect both public finances and public safety.
This is part of a global pattern. For instance, Yasmine Motarjemi, Nestlé’s former Corporate Food Safety Manager, spent nearly 12 years in Swiss courts after being pushed out for raising food safety warnings, including about the toxic baby-product line tied to the 2008 melamine contamination in China. Nestlé was finally ordered to pay her for her retaliation claims in 2023.
While the Abbott and Nestle cases are part of different legal systems and different whistleblower protection programs, the lesson is the same: when internal controls fail and regulators are not in the room, whistleblowers are often the last line of defense against public harm.
Finally, in one more thread to watch arising from the Abbott settlement, the Wall Street Journal reported that while DOJ had been weighing criminal charges, senior DOJ leadership closed the parallel criminal investigation in favor of this civil resolution. That decision has recently drawn Congressional scrutiny, and we will need to stay tuned to see where that goes.
So, what’s the takeaway? For manufacturers selling to WIC, Medicaid, or any government program: your certifications are only as good as what is happening on the plant floor. And for anyone on the inside who sees something, the False Claims Act exists as a way for you to alert and protect taxpayers – and receive a reward for undertaking the risks of speaking out.
EDITOR’S NOTE:
The opinions expressed in this article are solely those of the author and do not necessarily represent the views or opinions of MedLearn Media. We provide a platform for diverse perspectives, but the content and opinions expressed herein are the author’s own. MedLearn Media does not endorse or guarantee the accuracy of the information presented. Readers are encouraged to critically evaluate the content and conduct their own research. Any actions taken based on this article are at the reader’s own discretion.

















